Edwards Expands Peripheral Vascular Stent Pipeline With Orbus Deal
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' licensing agreement with Orbus Medical Technologies marks a decisive step toward enhancing its peripheral vascular disease treatments following the divestment phase of its reorganization strategy
You may also be interested in...
Edwards Sidesteps Crowded Coronary Stent Field, Targets Peripheral Stents
Edwards Lifesciences' vascular division will focus on peripheral stent technology development for the next few years, foregoing the significantly larger coronary stent market
Edwards Sidesteps Crowded Coronary Stent Field, Targets Peripheral Stents
Edwards Lifesciences' vascular division will focus on peripheral stent technology development for the next few years, foregoing the significantly larger coronary stent market
Edwards Pumps R&D Money Into Peripheral Stents Set To Launch In 2003
Edwards Lifesciences will hire 10-20 European sales representatives by 2003 to support the launch of a new line of peripheral stents